Glatiramer acetate was approved for marketing in the U.K. in August 2000, and launched in December.
Glatiramer povzroči premik populacije limfocitov T iz oblike proinflamatornih celic pomagalk Th1 v regulatorne celice Th2, ki zavirajo vnetni odziv.